Moderna’s (MRNA) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Moderna (NASDAQ:MRNA) in a research note released on Thursday, Benzinga reports.

A number of other equities research analysts have also recently issued reports on MRNA. Royal Bank of Canada reiterated an outperform rating and set a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Jefferies Financial Group reaffirmed a buy rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Canaccord Genuity Group boosted their price target on Moderna from $82.00 to $91.00 and gave the stock a hold rating in a research report on Friday, February 23rd. William Blair reaffirmed a market perform rating on shares of Moderna in a research report on Monday, April 1st. Finally, HSBC reissued a reduce rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Hold and an average price target of $129.55.

Moderna Stock Down 0.5 %

NASDAQ:MRNA opened at $125.00 on Thursday. The company has a market cap of $47.86 billion, a price-to-earnings ratio of -7.98 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 4.03. The stock’s fifty day moving average price is $105.05 and its two-hundred day moving average price is $94.48. Moderna has a 52-week low of $62.55 and a 52-week high of $142.79.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 earnings per share. On average, analysts anticipate that Moderna will post -7.47 EPS for the current year.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the sale, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the transaction, the director now owns 2,026,931 shares of the company’s stock, valued at $224,827,186.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders sold a total of 139,954 shares of company stock worth $14,822,576 in the last three months. 15.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP increased its holdings in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association increased its stake in shares of Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after buying an additional 102 shares during the period. Principle Wealth Partners LLC increased its stake in shares of Moderna by 4.3% in the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after buying an additional 102 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after acquiring an additional 115 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after acquiring an additional 116 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.